Spruce Biosciences
SPRB
38 hedge funds and large institutions have $68.7M invested in Spruce Biosciences in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 10 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
8% less capital invested
Capital invested by funds: $74.5M → $68.7M (-$5.8M)
14% less funds holding
Funds holding: 44 → 38 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
+$613K |
| 2 |
Two Sigma Advisers
New York
|
+$451K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$351K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$272K |
| 5 |
BlackRock
New York
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.63M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.04M |
| 3 |
AC
Armistice Capital
New York
|
-$958K |
| 4 |
Goldman Sachs
New York
|
-$404K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$204K |
SPRB Hedge Fund Activity: Q2 2023 in Review
38 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2023, worth a combined $68.7M — down 7.8% from $74.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SPRB and 4 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $613K. The largest seller was Citadel Advisors, cutting an estimated $3.63M.
- 38 institutional investors held Spruce Biosciences (SPRB) as of Q2 2023, down from 44 in Q1 2023.
- Funds reported $68.7M of Spruce Biosciences stock for Q2 2023, down 7.8% quarter-over-quarter.
- 4 funds opened new Spruce Biosciences positions in Q2 2023 and 10 closed out, a net change of -6 holders.
- The largest Spruce Biosciences buyer in Q2 2023 was Acuitas Investments, an estimated $613K added.
- The largest Spruce Biosciences seller in Q2 2023 was Citadel Advisors, an estimated $3.63M sold.
Based on aggregated 13F filings for Q2 2023.